BioCryst Pharmaceuticals
BCRXBioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug RAPIVAB was approved by FDA in Dec 2014.
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2022-2024
All insider trades at BioCryst Pharmaceuticals
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 6/15/2023 | Sell | Sanders, Machelle | Director | $8.0 | $31,920 |
| 6/14/2023 | Sell | Hutson, Nancy J. | Director | $8.0 | $103,443 |
| 4/3/2023 | Sell | Thackray, Helen M. | Chief R&D Officer | $8.3 | $58,030 |
| 2/1/2023 | Sell | Stonehouse, Jon P. | President & CEO | $10.4 | $1,038,000 |
| 12/15/2022 | Sell | Barnes, Alane P. | Chief Legal Officer | $10.9 | $45,424 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)